Clusters of SARS-CoV-2 lineage B.1.1.7 infection after vaccination with adenovirus-vectored and inactivated vaccines

William M. de Souza; Stéfanie P. Muraro; Gabriela F. Souza; Mariene R. Amorim; Renata Sesti-Costa; Luciana S. Mofatto; Julia Forato; Priscilla P. Barbosa; Daniel A. Toledo-Teixeira; Karina Bispo-Dos-santos; Pierina L. Parise; Natalia S. Brunetti; Joselia C.O. Moreira; Vitor A. Costa; Daniela M. Cardozo; Maria L. Moretti; Silvia Barros-Mazon; Gabriela F. Marchesi; Christiane Ambrosio; Fernando R. Spilki; Valeria C. Almeida; Andre S. Vieira; Lair Zambon; Alessandro S. Farias; Marcelo Addas-Carvalho; Bruno D. Benites; Rafael E. Marques; Ester C. Sabino; Andrea B. Von Zuben; Scott C. Weaver; Nuno R. Faria; Fabiana Granja; Rodrigo N. Angerami; José Luiz Proença-Módena

doi:10.3390/v13112127

Clusters of SARS-CoV-2 lineage B.1.1.7 infection after vaccination with adenovirus-vectored and inactivated vaccines

William M. de Souza, Stéfanie P. Muraro, Gabriela F. Souza, Mariene R. Amorim, Renata Sesti-Costa, Luciana S. Mofatto, Julia Forato, Priscilla P. Barbosa, Daniel A. Toledo-Teixeira, Karina Bispo-Dos-santos, Pierina L. Parise, Natalia S. Brunetti, Joselia C.O. Moreira, Vitor A. Costa, Daniela M. Cardozo, Maria L. Moretti, Silvia Barros-Mazon, Gabriela F. Marchesi, Christiane Ambrosio, Fernando R. SpilkiValeria C. Almeida, Andre S. Vieira, Lair Zambon, Alessandro S. Farias, Marcelo Addas-Carvalho, Bruno D. Benites, Rafael E. Marques, Ester C. Sabino, Andrea B. Von Zuben, Scott C. Weaver, Nuno R. Faria, Fabiana Granja, Rodrigo N. Angerami, José Luiz Proença-Módena

Microbiology, Immunology, and Molecular Genetics

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased trans-missibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, n = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, n = 52) for breakthrough infection rates for ChAdOx1 of 63.6% and 52.4% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had ~1.8–3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.

Original language	English
Article number	2127
Journal	Viruses
Volume	13
Issue number	11
DOIs	https://doi.org/10.3390/v13112127
State	Published - Nov 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Funding

Funding: This study was supported by grants from São Paulo Research Foundation (FAPESP, grant nos. 2016/00194-8 and 2020/04558-0), Fundo de Apoio ao Ensino, Pesquisa e Extensão from UNI-CAMP (FAEPEX-UNICAMP, grant no. 2266/20). This study was also supported by MCTI through the Rede Corona-ômica Brazil/MCTI (funded by the Financier of Studies and Projects [FINEP] grant no. 01.20.0003.00), RedeVírus/MCTI (FINEP grant no. 01.20.0029.000462/20), and the Brazilian National Council for Scientific and Technological Development, CNPq, grant no. 404096/2020-4). J.L.P.-M. is supported by CNPq grant no. 305628/2020-8. W.M.d.S. was supported by FAPESP, grant nos. 2017/13981-0, 2019/24251-9 and CNPq grant no. 408338/2018-0. R.S.C was funded by FAPESP, grant no. 2019/09704-7. B.D.B was supported by CNPq grant no. 401977/2020-0. S.P.M., G.F.S., K.B.d.-S., and P.L.P. were supported by FAPESP fellowships (2018/13645-3, 2018/10224-7, 2020/02159-0, and 2017/26908-0). M.R.A. and P.P.B. were supported by Coordination for the Improvement of Higher Education Personnel (CAPES, grant nos. 88887.356527/2019-00, 88887.513267/2020-00) fellowships, whereas D.A.T.-T. and L.S.M. were supported by CNPq fellowships (grant nos. 141844/2019-1 and 382206/2020-7). N.R.F. was supported by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (grant no. 204311/Z/16/Z). This project was supported by the Medical Research Council and FAPESP-Brazil-UK Center for (Arbo)virus Discovery, Diagnosis, Genomics, and Epidemiology partnership award (MR/S0195/1 and FAPESP 2018/14389-0). S.C.W. was supported by NIH grant AI120942. This study was supported by grants from S?o Paulo Research Foundation (FAPESP, grant nos. 2016/00194-8 and 2020/04558-0), Fundo de Apoio ao Ensino, Pesquisa e Extens?o from UNI-CAMP (FAEPEX-UNICAMP, grant no. 2266/20). This study was also supported by MCTI through the Rede Corona-?mica Brazil/MCTI (funded by the Financier of Studies and Projects [FINEP] grant no. 01.20.0003.00), RedeV?rus/MCTI (FINEP grant no. 01.20.0029.000462/20), and the Brazilian National Council for Scientific and Technological Development, CNPq, grant no. 404096/2020-4). J.L.P.-M. is supported by CNPq grant no. 305628/2020-8. W.M.d.S. was supported by FAPESP, grant nos. 2017/13981-0, 2019/24251-9 and CNPq grant no. 408338/2018-0. R.S.C was funded by FAPESP, grant no. 2019/09704-7. B.D.B was supported by CNPq grant no. 401977/2020-0. S.P.M., G.F.S., K.B.d.-S., and P.L.P. were supported by FAPESP fellowships (2018/13645-3, 2018/10224-7, 2020/02159-0, and 2017/26908-0). M.R.A. and P.P.B. were supported by Coordination for the Improvement of Higher Education Personnel (CAPES, grant nos. 88887.356527/2019-00, 88887.513267/2020-00) fellowships, whereas D.A.T.-T. and L.S.M. were supported by CNPq fellowships (grant nos. 141844/2019-1 and 382206/2020-7). N.R.F. was supported by a Wellcome Trust and Royal Society Sir Henry Dale Fel-lowship (grant no. 204311/Z/16/Z). This project was supported by the Medical Research Council and FAPESP-Brazil-UK Center for (Arbo)virus Discovery, Diagnosis, Genomics, and Epidemiology partnership award (MR/S0195/1 and FAPESP 2018/14389-0). S.C.W. was supported by NIH grant AI120942. Acknowledgments: We thank Thermo Fisher Scientific, which kindly provided an EVOS inverted microscope for the BSL3 facility at Emerging Viruses Laboratory, as well as the UNICAMP-Task-Force against COVID-19 that facilitated this study. Team of professionals from Vigil?ncia em Sa?de do Distrito de Sa?de Leste, DEVISA, Campinas for their support in obtaining clinical and epidemiologi-cal information related to the outbreaks. Lastly, the Brazilian Ministry of Science, Technology, and Innovation (MCTI) and all members of the Corona-?mica network are thanked for their support.

Funders	Funder number
Brazilian Ministry of Science, Technology, and Innovation
FAEPEX-UNICAMP	2266/20
FAPESP-Brazil-UK Center	2018/14389-0, MR/S0195/1
Financier of Studies and Projects
Fundo de Apoio ao Ensino, Pesquisa e Extens?o
Fundo de Apoio ao Ensino, Pesquisa e Extensão
Royal Society Sir Henry Dale Fel-lowship
Royal Society Sir Henry Dale Fellowship	204311/Z/16/Z
UNI-CAMP
National Institutes of Health (NIH)	AI120942
National Institutes of Health (NIH)
Wellcome Trust
Medical Research Council
Fundação de Amparo à Pesquisa do Estado de São Paulo	2016/00194-8, 2020/04558-0
Fundação de Amparo à Pesquisa do Estado de São Paulo
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior	88887.513267/2020-00, 88887.356527/2019-00, 141844/2019-1, 382206/2020-7
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Ministério da Ciência, Tecnologia e Inovação
Conselho Nacional de Desenvolvimento Científico e Tecnológico	2019/09704-7, 305628/2020-8, 408338/2018-0, 2017/26908-0, 2018/10224-7, 2020/02159-0, 404096/2020-4, 2018/13645-3, 2017/13981-0, 2019/24251-9, 401977/2020-0
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Financiadora de Estudos e Projetos	01.20.0029.000462/20, 01.20.0003.00
Financiadora de Estudos e Projetos

Keywords

B.1.1.7
COVID-19
Outbreak
SARS-CoV-2
Vaccine
Variant of concern

ASJC Scopus subject areas

Infectious Diseases
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v13112127

Cite this

de Souza, W. M., Muraro, S. P., Souza, G. F., Amorim, M. R., Sesti-Costa, R., Mofatto, L. S., Forato, J., Barbosa, P. P., Toledo-Teixeira, D. A., Bispo-Dos-santos, K., Parise, P. L., Brunetti, N. S., Moreira, J. C. O., Costa, V. A., Cardozo, D. M., Moretti, M. L., Barros-Mazon, S., Marchesi, G. F., Ambrosio, C., ... Proença-Módena, J. L. (2021). Clusters of SARS-CoV-2 lineage B.1.1.7 infection after vaccination with adenovirus-vectored and inactivated vaccines. Viruses, 13(11), Article 2127. https://doi.org/10.3390/v13112127

@article{b2636883ddf24e77a24d78565587e094,

title = "Clusters of SARS-CoV-2 lineage B.1.1.7 infection after vaccination with adenovirus-vectored and inactivated vaccines",

abstract = "A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased trans-missibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, n = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, n = 52) for breakthrough infection rates for ChAdOx1 of 63.6\% and 52.4\% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had \textasciitilde{}1.8–3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.",

keywords = "B.1.1.7, COVID-19, Outbreak, SARS-CoV-2, Vaccine, Variant of concern",

author = "\{de Souza\}, \{William M.\} and Muraro, \{St{\'e}fanie P.\} and Souza, \{Gabriela F.\} and Amorim, \{Mariene R.\} and Renata Sesti-Costa and Mofatto, \{Luciana S.\} and Julia Forato and Barbosa, \{Priscilla P.\} and Toledo-Teixeira, \{Daniel A.\} and Karina Bispo-Dos-santos and Parise, \{Pierina L.\} and Brunetti, \{Natalia S.\} and Moreira, \{Joselia C.O.\} and Costa, \{Vitor A.\} and Cardozo, \{Daniela M.\} and Moretti, \{Maria L.\} and Silvia Barros-Mazon and Marchesi, \{Gabriela F.\} and Christiane Ambrosio and Spilki, \{Fernando R.\} and Almeida, \{Valeria C.\} and Vieira, \{Andre S.\} and Lair Zambon and Farias, \{Alessandro S.\} and Marcelo Addas-Carvalho and Benites, \{Bruno D.\} and Marques, \{Rafael E.\} and Sabino, \{Ester C.\} and \{Von Zuben\}, \{Andrea B.\} and Weaver, \{Scott C.\} and Faria, \{Nuno R.\} and Fabiana Granja and Angerami, \{Rodrigo N.\} and Proen{\c c}a-M{\'o}dena, \{Jos{\'e} Luiz\}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = nov,

doi = "10.3390/v13112127",

language = "English",

volume = "13",

number = "11",

}

de Souza, WM, Muraro, SP, Souza, GF, Amorim, MR, Sesti-Costa, R, Mofatto, LS, Forato, J, Barbosa, PP, Toledo-Teixeira, DA, Bispo-Dos-santos, K, Parise, PL, Brunetti, NS, Moreira, JCO, Costa, VA, Cardozo, DM, Moretti, ML, Barros-Mazon, S, Marchesi, GF, Ambrosio, C, Spilki, FR, Almeida, VC, Vieira, AS, Zambon, L, Farias, AS, Addas-Carvalho, M, Benites, BD, Marques, RE, Sabino, EC, Von Zuben, AB, Weaver, SC, Faria, NR, Granja, F, Angerami, RN & Proença-Módena, JL 2021, 'Clusters of SARS-CoV-2 lineage B.1.1.7 infection after vaccination with adenovirus-vectored and inactivated vaccines', Viruses, vol. 13, no. 11, 2127. https://doi.org/10.3390/v13112127

TY - JOUR

T1 - Clusters of SARS-CoV-2 lineage B.1.1.7 infection after vaccination with adenovirus-vectored and inactivated vaccines

AU - de Souza, William M.

AU - Muraro, Stéfanie P.

AU - Souza, Gabriela F.

AU - Amorim, Mariene R.

AU - Sesti-Costa, Renata

AU - Mofatto, Luciana S.

AU - Forato, Julia

AU - Barbosa, Priscilla P.

AU - Toledo-Teixeira, Daniel A.

AU - Bispo-Dos-santos, Karina

AU - Parise, Pierina L.

AU - Brunetti, Natalia S.

AU - Moreira, Joselia C.O.

AU - Costa, Vitor A.

AU - Cardozo, Daniela M.

AU - Moretti, Maria L.

AU - Barros-Mazon, Silvia

AU - Marchesi, Gabriela F.

AU - Ambrosio, Christiane

AU - Spilki, Fernando R.

AU - Almeida, Valeria C.

AU - Vieira, Andre S.

AU - Zambon, Lair

AU - Farias, Alessandro S.

AU - Addas-Carvalho, Marcelo

AU - Benites, Bruno D.

AU - Marques, Rafael E.

AU - Sabino, Ester C.

AU - Von Zuben, Andrea B.

AU - Weaver, Scott C.

AU - Faria, Nuno R.

AU - Granja, Fabiana

AU - Angerami, Rodrigo N.

AU - Proença-Módena, José Luiz

PY - 2021/11

Y1 - 2021/11

N2 - A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased trans-missibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, n = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, n = 52) for breakthrough infection rates for ChAdOx1 of 63.6% and 52.4% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had ~1.8–3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.

AB - A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased trans-missibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, n = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, n = 52) for breakthrough infection rates for ChAdOx1 of 63.6% and 52.4% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had ~1.8–3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.

KW - B.1.1.7

KW - COVID-19

KW - Outbreak

KW - SARS-CoV-2

KW - Vaccine

KW - Variant of concern

UR - https://www.scopus.com/pages/publications/85117940333

UR - https://www.scopus.com/inward/citedby.url?scp=85117940333&partnerID=8YFLogxK

U2 - 10.3390/v13112127

DO - 10.3390/v13112127

M3 - Article

AN - SCOPUS:85117940333

SN - 1999-4915

VL - 13

JO - Viruses

JF - Viruses

IS - 11

M1 - 2127

ER -

Clusters of SARS-CoV-2 lineage B.1.1.7 infection after vaccination with adenovirus-vectored and inactivated vaccines

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this